Global Geriatric Medicines Industry Outlook 2025-2029: Market Set to Cross $2578.21 Billion Milestone

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Geriatric Medicines Market Size By 2025?
The market concerning medicines for the elderly has experienced swift expansion of late, projections indicating an increase from a valuation of $1227.91 billion in the year 2024 to $1427.01 billion in 2025, reflecting a compound annual growth rate of 16.2%. This upward trajectory throughout the past period stems from several factors, including the heightened occurrence of strokes, a greater presence of long-term illnesses, the rising incidence of heart and blood vessel ailments, augmented governmental backing, and a greater focus placed upon tailored medical treatments.

How Big Is the Geriatric Medicines Market Size Expected to Grow by 2029?
Anticipation surrounds the geriatric medicines sector, projecting swift expansion ahead; by 2029, its valuation is projected to reach $2578.21 billion, propelled by a compound annual growth rate of 15.9% throughout the projection timeframe. This escalating trajectory is fundamentally driven by the growing frequency of health issues tied to aging, the escalating global elderly demographic, increased spending within the healthcare domain, greater adoption of specialized geriatric remedies, and the heightened occurrence of hypertension cases. Key shifts expected to influence this period encompass the integration of digital pill technology and wearable monitoring apparatus, the creation of methodologies and systems designed for the secure handling of polypharmacy, breakthroughs in both stem cell applications and gene-based treatments, the wider utilization of remote healthcare services, and progress in identifying and averting age-associated ailments earlier in their development.

View the full report here:
https://www.thebusinessresearchcompany.com/report/geriatric-medicines-global-market-report

Which Key Market Drivers Powering Geriatric Medicines Market Expansion and Growth?
The expanding incidence of health issues associated with aging is anticipated to fuel the expansion of the geriatric pharmaceuticals sector in the foreseeable future. These age-related ailments, characterized by a heightened frequency or severity as individuals grow older due to the natural aging process, are largely spurred by extended lifespans, progress in medical care, and a growing proportion of elderly individuals in the population. Geriatric medications offer targeted therapies for older individuals, thereby aiding in the management of these age-related conditions which subsequently enhance their well-being and healthcare results. A specific illustration of this trend involved musculoskeletal (MSK) conditions, such as arthritis or persistent back and joint difficulties; in 2022, data from a UK governmental body, the Office for Health Improvement and Disparities (OHID), indicated that 17.6% of the population aged sixteen and above reported suffering from such a long-term condition, a rise from the 17.0% recorded the previous year in 2021, clearly establishing the rising prevalence of diseases linked to aging as a key factor propelling the geriatric medicines market forward.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20817&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Geriatric Medicines Market?
Key players within the geriatric medication sector are concentrating their efforts on pioneering diabetes treatments as the need for superior management options among older adults escalates.These novel therapeutic interventions for diabetes are designed to either significantly improve existing management protocols or present curative pathways that outperform conventional methods, thereby boosting effectiveness, patient security, and overall results for individuals.To illustrate, in the month of August 2023, Akums Drugs & Pharmaceuticals Ltd., a pharmaceutical entity operating out of India that specializes in contract manufacturing, revealed the commencement of sales for a new combined treatment integrating Vildagliptin SR alongside Metformin SR.This cutting-edge formulation has been specifically engineered to tackle the challenges associated with administering Type 2 diabetes care to seniors, aiming for robust blood sugar regulation while mitigating common adverse effects like low blood sugar episodes and unwanted weight increase, factors of paramount importance for this age bracket.Through the combined action of these two pharmaceuticals, there is an amplified stimulation of insulin release and a reliable reduction in glucose levels, offering assurance regarding both safety and beneficial impact, and this particular offering has successfully secured the necessary authorizations from the Drug Controller General of India (DCGI).

What Are the Emerging Segments in the Geriatric Medicines Market?
The geriatric medicinesmarket covered in this report is segmented -

1) By Therapeutics: Analgesics; Antihypertensive; Statins; Proton Pump Inhibitors; Anticoagulant; Antipsychotic; Other Therapeutics
2) By Condition: Cardiovascular; Arthritis; Neurological; Cancer; Osteoporosis; Respiratory; Other Conditions
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

Subsegments:
1) By Analgesics: Non-Opioid Analgesics (Acetaminophen, NSAIDs); Opioid Analgesics (Morphine, Oxycodone); Topical Analgesics (Lidocaine Patches)
2) By Antihypertensive: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Beta-Blockers; Calcium Channel Blockers; Diuretics; Alpha-Blockers
3) By Statins: Atorvastatin; Simvastatin; Rosuvastatin; Pravastatin; Lovastatin
4) By Proton Pump Inhibitors: Omeprazole; Esomeprazole; Lansoprazole; Pantoprazole; Rabeprazole
5) By Anticoagulant: Warfarin; Direct Oral Anticoagulants (DOACs): Dabigatran, Rivaroxaban, Apixaban; Heparin
6) By Antipsychotic: Atypical Antipsychotics; Typical Antipsychotics
7) By Other Therapeutics: Antidepressants (SSRIs, SNRIs); Antidiabetic Medications (Insulin, Metformin); Anticonvulsants; Anti-Inflammatory Drugs (Corticosteroids); Cognitive Enhancers (Donepezil, Memantine)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=20817&type=smp

Who Are the Global Leaders in the Geriatric Medicines Market?
Major companies operating in the geriatric medicines market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Apotex Inc., Intas Pharmaceuticals Limited, Dr. Reddy's Laboratories, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Endo Pharmaceuticals Inc.

Which are the Top Profitable Regional Markets for the Geriatric Medicines Industry?
North America was the largest region in the geriatric medicines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geriatric medicines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20817

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.